New Drug Approvals
| 1 | Marzulene S Combination Granules | Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent （1968：Japan, 1990：China, 2000：India） |
| Marzulene Combination Tablets 1.0ES | （Dosage form addition, 2003：Japan） | |
| Marzulene Combination Tablets 0.5ES | （Dosage form addition, 2008：Japan） | |
| Marzulene Combination Tablets 0.375ES | （Dosage form addition, 2009：Japan） | |
| 2 | AZULOXAⓇ Granules 2.5% | Gastric ulcer therapeutic agent （2001：Japan, 2004：Korea） |
| AZULOXAⓇ Tablets 15mg | （Dosage form addition, 2011：Japan） | |
| 3 | SuglatⓇ Tablets 25mg/50mg （Ipragliflozin (ASP1941) ） |
Diabetes therapeutic agent/Selective SGLT2 Inhibitor （Type 2 Diabetes, 2014：Japan, 2015：Korea, 2019：Russia, Joint development with Astellas Pharma Inc.） （Type 1 Diabetes, 2018：Japan, Joint development with Astellas Pharma Inc.） |
| 4 | SUJANUⓇ Combination Tablets （Ipragliflozin/Sitagliptin (MK-0431J) ） |
Type 2 Diabetes therapeutic agent/Selective DPP-4 inhibitor/Selective SGLT2 Inhibitor （2018：Japan, Joint development with Astellas Pharma Inc and MSD.） |
| 5 | XOSPATAⓇ Tablets 40mg （giliteritinib (ASP2215) ） |
Antineoplastic drug/FLT3 Mutation （2018：Japan/US, 2019：Europe/Canada, 2020：Taiwan/Korea/Brazil/Australia, 2021：China/Singapore, Joint development with Astellas Pharma Inc.） |
R&D Pipeline（2025.4）
| 1 | ASP1570 | ①Development stage：Global/Phase Ⅰ ②Target：Cancer ③Development：Astellas |
| 2 | ASP2215 （giliteritinib） | ①Development stage：Global/Phase Ⅲ ②Target：Acute myeloid leukemia ③Development：Astellas |
| 3 | S-556971（KT6-971） | ①Development stage：Japan/Phase Ⅱ, Europe/Phase I ②Target：Dyslipidemia ③Development：Kotobuki |
| 4 | KT7-533: α-C-Galactosyl Ceramide
| （Phase I in preparation：Derivation ending） |
